251 related articles for article (PubMed ID: 31610081)
1. Nonalcoholic Steatohepatitis After Liver Transplantation.
Cotter TG; Charlton M
Liver Transpl; 2020 Jan; 26(1):141-159. PubMed ID: 31610081
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Risks for Nonalcoholic Fatty Liver Disease and Steatohepatitis Post-liver Transplant: Systematic Review and Meta-analysis.
Saeed N; Glass L; Sharma P; Shannon C; Sonnenday CJ; Tincopa MA
Transplantation; 2019 Nov; 103(11):e345-e354. PubMed ID: 31415032
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
Mikolasevic I; Filipec-Kanizaj T; Mijic M; Jakopcic I; Milic S; Hrstic I; Sobocan N; Stimac D; Burra P
World J Gastroenterol; 2018 Apr; 24(14):1491-1506. PubMed ID: 29662288
[TBL] [Abstract][Full Text] [Related]
4. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis.
Charlton M
Curr Opin Organ Transplant; 2013 Jun; 18(3):251-8. PubMed ID: 23652610
[TBL] [Abstract][Full Text] [Related]
5. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation.
Kappus M; Abdelmalek M
Clin Liver Dis; 2017 May; 21(2):321-335. PubMed ID: 28364816
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times.
Gitto S; Marra F; De Maria N; Bihl F; Villa E; Andreone P; Burra P
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):173-178. PubMed ID: 30791778
[TBL] [Abstract][Full Text] [Related]
7. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M
Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic steatohepatitis in posttransplantation liver: Review article.
Andrade ARCF; Cotrim HP; Bittencourt PL; Almeida CG; Sorte NCAB
Rev Assoc Med Bras (1992); 2018 Feb; 64(2):187-194. PubMed ID: 29641680
[TBL] [Abstract][Full Text] [Related]
9. Increasing nonalcoholic steatohepatitis overlap in liver transplant recipients: Additive risk for de novo malignancy.
Nasser-Ghodsi N; Mara K; Allen AM; Watt KD
Clin Transplant; 2022 Aug; 36(8):e14714. PubMed ID: 35594161
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation.
Sourianarayanane A; Arikapudi S; McCullough AJ; Humar A
Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):481-487. PubMed ID: 28253211
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic steatohepatitis recurrence after liver transplant.
Taneja S; Roy A
Transl Gastroenterol Hepatol; 2020; 5():24. PubMed ID: 32258528
[TBL] [Abstract][Full Text] [Related]
12. Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes.
Cholankeril G; Wong RJ; Hu M; Perumpail RB; Yoo ER; Puri P; Younossi ZM; Harrison SA; Ahmed A
Dig Dis Sci; 2017 Oct; 62(10):2915-2922. PubMed ID: 28744836
[TBL] [Abstract][Full Text] [Related]
13. Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation.
Germani G; Laryea M; Rubbia-Brandt L; Egawa H; Burra P; OʼGrady J; Watt KD
Transplantation; 2019 Jan; 103(1):57-67. PubMed ID: 30335694
[TBL] [Abstract][Full Text] [Related]
14. Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016.
Golabi P; Bush H; Stepanova M; Locklear CT; Jacobson IM; Mishra A; Trimble G; Erario M; Venkatesan C; Younossi I; Goodman Z; Younossi ZM
Medicine (Baltimore); 2018 Aug; 97(31):e11518. PubMed ID: 30075518
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic Steatohepatitis: A Review.
Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
[TBL] [Abstract][Full Text] [Related]
16. International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation.
Tsochatzis E; Coilly A; Nadalin S; Levistky J; Tokat Y; Ghobrial M; Klinck J; Berenguer M
Transplantation; 2019 Jan; 103(1):45-56. PubMed ID: 30153225
[TBL] [Abstract][Full Text] [Related]
17. Liver Transplantation and Bariatric Surgery: Timing and Outcomes.
Diwan TS; Rice TC; Heimbach JK; Schauer DP
Liver Transpl; 2018 Sep; 24(9):1280-1287. PubMed ID: 30080949
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation.
Tokodai K; Karadagi A; Kjaernet F; Romano A; Ericzon BG; Nowak G
Scand J Gastroenterol; 2019 Feb; 54(2):233-239. PubMed ID: 30999770
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation.
Carter D; Dieterich DT; Chang C
Clin Liver Dis; 2018 Feb; 22(1):213-227. PubMed ID: 29128058
[TBL] [Abstract][Full Text] [Related]
20. The Role of Beta-7 Integrin and Carbonic Anhydrase IX in Predicting the Occurrence of de Novo Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.
Ester C; Cerban R; Iacob S; Pietrareanu C; Constantin G; Paslaru L; Ichim S; Lita M; Vadan R; Grancea C; Ruta S; Gheorghe C; Popescu I; Gheorghe L
Chirurgia (Bucur); 2018; 113(4):534-541. PubMed ID: 30183584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
